Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 4/20 | 0.38 |
| ▸ | GLA | P06280 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2108798 | 0.91 | EPHX1 (0.41) | EPHX1ALDH1A1LMNAMAPTALOX12 | |
| SCHEMBL8034193 | 0.91 | EPHX1 (0.41) | EPHX1ALDH1A1LMNAMAPTALOX12 | |
| SCHEMBL2108797 | 0.91 | EPHX1 (0.41) | EPHX1ALDH1A1LMNAMAPTALOX12 | |
| SCHEMBL2631696 | 0.89 | EPHX1 (0.39) | EPHX1ALDH1A1LMNAMAPTALOX12 | |
| SCHEMBL2108331 | 0.89 | EPHX1 (0.39) | EPHX1ALDH1A1LMNAMAPTALOX12 | |
| SCHEMBL3773875 | 0.89 | EPHX1 (0.39) | EPHX1ALDH1A1LMNAMAPTALOX12 | |
| SCHEMBL2619901 | 0.89 | EPHX1 (0.39) | EPHX1ALDH1A1LMNAMAPTALOX12 | |
| SCHEMBL3803423 | 0.87 | EPHX1 (0.42) | EPHX1ALDH1A1LMNAMAPTALOX12 | |
| SCHEMBL2631629 | 0.87 | EPHX1 (0.42) | EPHX1ALDH1A1LMNAMAPTALOX12 | |
| SCHEMBL18597910 | 0.87 | EPHX1 (0.42) | EPHX1ALDH1A1LMNAMAPTALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9175013-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-11-03 | — | — | US | disclosed |
| US-9175013-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-11-03 | — | — | US | disclosed |
| US-20140179690-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
| US-20140179690-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
| EP-2665731-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2013-11-27 | — | — | EP | disclosed |
| WO-2012098461-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012098461-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179690-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | EPHX1 1120/4885ALDH1A1 1346/4885LMNA 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.